Medtide Inc. (stock code: 03880.HK) announced the completion of its H-share full-circulation programme, converting 68.20 million previously unlisted domestic shares into H shares. Trading in the newly converted shares will commence on the Hong Kong Stock Exchange at 9:00 a.m. on 10 March 2026.

Prior to the conversion, MEDTIDE’s H-share capital stood at 73.60 million shares, representing 51.90 % of its total issued share capital. Following the conversion, the company’s entire issued share base of 141.80 million shares is now listed in Hong Kong, expanding the public float to 100 %.

Key timeline: • 27 July 2025 – Company submitted its full-circulation application. • 5 February 2026 – China Securities Regulatory Commission issued the filing notice. • 9 March 2026 – Conversion completed; listing of converted shares set for 10 March 2026.

Shareholders are advised to exercise caution when dealing in MEDTIDE’s H shares. The board is chaired by Dr. Xu Qi, who also serves as Chief Executive Officer.